<SEC-DOCUMENT>0001104659-21-101016.txt : 20210805
<SEC-HEADER>0001104659-21-101016.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805210705
ACCESSION NUMBER:		0001104659-21-101016
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210805
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Redmile Group, LLC
		CENTRAL INDEX KEY:			0001425738
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		211150312

	BUSINESS ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		BUILDING D, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129
		BUSINESS PHONE:		415-489-9980

	MAIL ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		BUILDING D, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Redmile Biopharma Investments III, L.P.
		CENTRAL INDEX KEY:			0001838746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		211150310

	BUSINESS ADDRESS:	
		STREET 1:		LETTERMAN DIGITAL ARTS CENTER
		STREET 2:		ONE LETTERMAN DRIVE, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129
		BUSINESS PHONE:		415-489-9980

	MAIL ADDRESS:	
		STREET 1:		LETTERMAN DIGITAL ARTS CENTER
		STREET 2:		ONE LETTERMAN DRIVE, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Green Jeremy
		CENTRAL INDEX KEY:			0001650527

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		211150311

	MAIL ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE, BUILDING D
		STREET 2:		SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001832038
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851403134
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		303 WYMAN STREET
		STREET 2:		SUITE 300
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 530-3600

	MAIL ADDRESS:	
		STREET 1:		303 WYMAN STREET
		STREET 2:		SUITE 300
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>tm2124020-1_3seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-08-05</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001832038</issuerCik>
        <issuerName>Adagio Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ADGI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001425738</rptOwnerCik>
            <rptOwnerName>Redmile Group, LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>ONE LETTERMAN DRIVE, BUILDING D</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE D3-300</rptOwnerStreet2>
            <rptOwnerCity>SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94129</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001650527</rptOwnerCik>
            <rptOwnerName>Green Jeremy</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O REDMILE GROUP, LLC</rptOwnerStreet1>
            <rptOwnerStreet2>ONE LETTERMAN DRIVE, BLDG D SUITE D3-300</rptOwnerStreet2>
            <rptOwnerCity>SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94129</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001838746</rptOwnerCik>
            <rptOwnerName>Redmile Biopharma Investments III, L.P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O REDMILE GROUP, LLC</rptOwnerStreet1>
            <rptOwnerStreet2>ONE LETTERMAN DRIVE, BLDG D SUITE D3-300</rptOwnerStreet2>
            <rptOwnerCity>SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94129</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1920960</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Series C preferred stock (the &quot;Series C Preferred&quot;) is convertible into shares of the Issuer's common stock at any time at the holder's election, or automatically upon the closing of the Issuer's initial public offering, for no consideration. The Series C Preferred has no expiration date. This Form 3 reflects that, on July 30, 2021, the Issuer effected a five-for-one forward split of its common stock, as a result of which the conversion ratio of the Series C Preferred was proportionately adjusted.</footnote>
        <footnote id="F2">The Series C Preferred are directly owned by certain private investment vehicles managed by Redmile Group, LLC (&quot;Redmile&quot;), including Redmile Biopharma Investments III, L.P., which directly owns 1,440,725 shares of the Series C Preferred. The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Redmile and Mr. Green are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC</signatureName>
        <signatureDate>2021-08-05</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Jeremy Green</signatureName>
        <signatureDate>2021-08-05</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>By: /s/ Jeremy Green, Managing Member of Redmile Biopharma Investments III (GP), LLC, General Partner of Redmile Biopharma Investments III, L.P.</signatureName>
        <signatureDate>2021-08-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
